Trends, challenges, opportunities for early-stage biotech firms

02/20/2014 | Xconomy

The Affordable Care Act will accelerate a trend in the health care system away from volume-based fee-for-service models toward a population-based approach that will open opportunities for life sciences companies but will also increase concerns about reimbursement, writes Jeremy Halpern, a partner at the Nutter McClennen & Fish law firm. The tough investment climate will continue, and acquisition will continue to be the likely exit mechanism for life sciences companies, Halpern writes. "Given the tough investment climate and the challenges involved in conceptualizing, funding, and growing an early-stage biotech, creating good networks and having strong advocates on your side has never been more important," he writes.

View Full Article in:

Xconomy

Published in Briefs: